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Technetium-9 9 m-Labeled Chemotactic Peptides in 
Acute Infection and Sterile Inflammation
Conny J. van der Laken, Otto C. Boerman, Wim J.G. Oyen, Marjo T.P. van de Ven, D. Scott Edwards, John A. Barrett, 
Jos W.M. van der Meer and Frans H.M. Corstens
Departments o f  Nuclear Medicine and Internal Medicinet University Hospital Nijmegen, Nijmegen, The Netherlands; and 
Radiopharmaceuticals Division, The Da Pont Merck Pharmaceutical Company, North Billerica, Massachusetts
Chemotactic peptides have been proposed as vehicles to image 
infection and inflammation. Previous studies have shown high up­
take at the site of infection soon after injection, most likely because 
of specific binding to receptors on locally present leukocytes. To 
investigate this hypothesis, the in vivo behavior of a synthetic 
chemotactic peptide was compared to a control peptide of similar 
molecular weight with low receptor binding affinity. In addition, the 
potential to target to different infections and sterile inflammation was 
tested. Methods: Twenty-four hours after induction of Escherichia 
coli, Staphylococcus aureus and zymosan abscesses, rabbits were 
i.v. injected with either 1 mCi of 99nrrTc>labeled formyl-methionyl- 
Jeucyf-phenylalanyMysine-hydrazinonicotinamide (®9nTC“fMLFK- 
HYNIC) or 99mTc-labeled hydrazinonicotinamide-methionyl-leucyl- 
phenylalanyl-OMe (""Tc-HYNIC-MLFOMe, control peptide). 
Gamma camera images were obtained at 5 min and 1, 4, 8 and 20 
hr postinjection. Biodistribution was determined at 20 hr postinjec­
tion. Results: The blood clearances of 99mTc-fMLFK-HYNIC and 
99nrTc-HYNIC-MLF0Me were similar. With time, 99mTc-fMLFK- 
HYNIO was retained in the abscess (E. coli), whereas the control 
agent 99nTc-HYNIC~MLFOMe was cleared from the abscess 
(0.049 ± 0.011 versus 0.005 ± 0.0003%ID/g at 20 hr postinjection; 
p <  0.0005). Abscess-to-contralateral muscie ratios of 99mTc- 
fMLFK-HYNIC rose to 36.8 ±  4.3 at 20 hr postinjection. E coli, S. 
aureus and zymosan abscesses were clearly visualized from 4 hr 
postinjection onward. Abscess-to-background ratios increased to 
values varying from 4.4 ± 0.2 (zymosan) to 7.1 ± 0.6 (S. aureus) at 
20 hr postinjection. The uptake in S. aureus and zymosan abscesses 
did not differ significantly from the uptake in E. coli abscesses.
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Conclusion: fMLFK-HYNIC is retained in both acute infection and 
steriie inflammation by means of specific receptor binding if suffi­
cient cellular infiltration is present.
Key Words: chemotactic peptides; infection; inflammation; biodis­
tribution; imaging
J Nucl Med 1997; 38:1310-1315
D u r in g  the past few years, there has been a growing interest 
in the development of radiolabeled immunopeptides and pro­
teins as radiopharmaceuticals for the imaging of infection and 
inflammation. Their small size and receptor binding capacity 
may make radiolabeled immunopeptides suitable agents for the 
rapid detection of inflammatory foci. The potential of several 
immunopeptides and proteins has already been demonstrated 
(1-5). One promising approach is the use of chemotactic 
peptides (6).
Chemotactic peptides, released by bacteria, cause leukocytes 
to marginate to nearby endothelial surfaces, move extravascu- 
larly and accumulate at sites where a chemotactin has been 
generated, a process called chemotaxis (7). Migration of cells 
from the blood to sites of tissue damage in the extravascular 
tissue is crucial to the development o f  inflammation. Schiff- 
mann et al. (5) found that formyl peptides, synthetic analogs of  
natural bacterial products, were potent chemotactic factors for 
polymorphonuclear neutrophils (PMNs) and monocytes. These 
peptides initiate leukocyte chemotaxis by high-affmity binding 
to receptors present on both PMNs and mononuclear cells 
(9,10).
Fischman et al. (1) and Babich et al. (2) showed that acute 
infection in rats, rabbits and nonhuman primates can be clearly
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visualized by m In- and ;,mTc-labeled synthetic chemotactic 
peptides. Imaging of acute infection in rabbits with " niTc- 
labeled chemotactic peptides was superior to 11 ^In-labeled 
white blood cells. High target-to-background ratios were ob­
tained, probably as a result o f  accumulation o f the chemotactic 
peptide at the site of infection.
Until now, increasing target-to-background ratios were as­
sumed to be due to specific receptor binding of chemotactic 
peptides to leukocytes in inflammatory tissue, with concomitant 
clearance from the blood pool and other noninflamed tissues. 
These assumptions were based on correlations found between in 
vitro receptor binding and accumulation o f the peptides at the 
site of inflammation in vivo. In this study, the specificity of  
focal uptake was studied directly in vivo. The in vivo behavior 
of the chemotactic peptide N-formyl-methionyl-leucyl-phenyl- 
alanyl-lysine (fMLFK) was compared to the behavior o f  a 
size-matched control peptide with low receptor binding affinity. 
Furthermore, the potential of the chemotactic peptide to localize 
in different acute infections as well as in sterile inflammation 
was explored.
MATERIALS AND METHODS 
Peptide Synthesis
fMLFK was synthesized and purified as described by Fischman 
et al. (/) and conjugated to hydmzinonicotinic acid (HYNIC) as 
described by Babich et al. (11).
The peptide methionyl-leucyl-phenylalanyl-OMe (MLFOMe) 
was analogously synthesized and purified. HYNIC was conjugated 
to the N-terminal amine group of methionine. The peptide was used 
as control peptide in imaging and biodistribution studies.
Technetium-99m Labeling of HYNIC-Conjugated fMLFK 
and MLFOMe
In a 8-ml glass vial, 0.25 ml of 160 mg/ml tricine (in water), 
100 /¿I of 0.05 mg/ml fMLFK-HYNIC or HYNIC-MLFOMe (in 
DMSO), 0.5 ml of 50-70 mCi 9lJmTc04“ (in saline), 220 ¡A of 
ethanol and 30 ¡A of 1 mg/ml stannous chloride in 0.1 N HC1 were 
mixed and incubated at room temperature for 0.5-1 hr. Subse­
quently, 400 /x! of the reaction mixture was purified by reversed- 
phase chromatography using a 4.6 mm X 25 cm Zorbax Rx-C18 
column. The following elution conditions were used: solvent A, 
90% 25 mM sodium phosphate (pH 8) and 10% acetonitrile; 
solvent B, 50% 25 mM sodium phosphate (pH 8) and 50% 
acetonitrile; gradient, 0-100% solvent B over 25 min; flow rate, 
1.0 ml/min; and UV absorption, 280 nm. The void fractions were 
collected in plastic tubes containing tricine (20-30 mg per tube) 
and transferred to a 25-ml round-bottomed flask. The solution was 
evaporated to dryness and then reconstituted with saline to proper 
concentrations for animal studies.
The radiochemical purity of the radiopharmaceuticals was de­
termined by reversed-phase chromatography with the above de­
scribed elution conditions and instant thin-layer chromatography 
on paper Whatman no. 1 strips with acetone and acetone :saline 
(3:1) as solvents.
Receptor Binding Assays
Human PMNs were isolated from heparinized venous blood 
obtained from healthy donors. Blood samples of 40 ml were mixed 
with an equal volume of Hanks’ balanced salt solution (HBSS), 
layered on a Ficoll-Hypaque gradient and centrifuged at 10°C and 
1300 rpm for 30 min. The supernatant was discarded, and the 
PMN-rich pellet was resuspended in cold PIBSS, to which cold 2% 
dextran solution (in saline) was added to remove the contaminating 
red blood cells. After 25 min of sedimentation at room temperature, 
the suspended cells were removed and centrifuged at 10°C and 
1300 rpm for 10 min. The supernatant was discarded, and the pellet
was resuspended in 10 ml of cold hypotonic lysing buffer for a 
5-min lysis of residual RBCs. After lysis, cold HBSS (40 ml) was 
added, and the cells were centrifuged at 10°C and 1300 rpm for 10 
min. This final PMN pellet was washed once and resuspended to 
the desired cell concentration in phosphate buffered incubation 
buffer containing 140 mM  NaCl, 1.0 mM  KH2P 04, 5 mM  
Na2HP04, 0.5 mM  MgCl2, 0.15 mMCaCl2 and 0.5% BSA (pH 7.4) 
for fMLF binding assays. For the cytochrome C reduction assays, 
cells were resuspended in HBSS.
fMLF Binding Assay, [3H]fMLF (10 nM), fMLFK-HYNIC or 
HYNIC-MLFOMe and 100 ¡A o f PMN solution (8 X 106 PMNs/ 
ml) were added to a 96-well microplate with filters (0.65-juLin pore 
size). The microplate was incubated for 60 min at room tempera­
ture with gentle agitation. The microplate was then placed on a 
filtration system. The wells were washed with incubation buffer 
three times and dried. The filters were removed from the micro­
plate, placed into scintillation vials and agitated for 1 hr at room 
temperature in the presence of scintillation fluid. Percent inhibition 
of [3H]fMLF binding to PMNs was calculated by dividing the 
specific binding (total binding — nonspecific binding) obtained in 
the presence of fMLFK-HYNIC or HYNIC-MLFOMe by that 
obtained in the absence of these peptides. IC5() values were 
calculated by fitting the percent inhibition values to a regression 
line.
Cytochrome c PMN Free Radical Release Assay. The biologic 
activity of fMLFK-HYNIC was determined by measuring super­
oxide release of PMNs after they were exposed to fMLFK-HYNIC. 
Typically, PMN solution (1 ml, 1 X 106 PMN s/ml) was incubated 
with cytochalasin B (10 ¡jlM) and 100 [A of cytochrome c (40 [lM) 
for 10 min at 37°C, Then, fMLFK-HYNIC was added, and tubes 
were incubated for 10 min at room temperature. After centrifuga­
tion (200 X g, 10°C for 10 min), the supematants were transferred 
to cuvettes for spectrophotometric analysis to measure reduction of 
cytochrome c, reflecting the amount of superoxide release by 
PMNs. The percent of fMLFK-HYNIC response was determined. 
EC5() values were derived from concentration-response curves.
Animal Studies
Comparison of Technetium-99m-jMLFK-HYN!C and Tec hue- 
tium~99m~HYNIC-MLFOMe. Abscesses were induced in the left 
thigh muscle of female New Zealand rabbits weighing 2.2-2.8 kg 
with 1.5 X lO10 colony forming units of Escherichia coli in 0,5 ml. 
During the procedure, the rabbits were anesthetized with a subcu­
taneous injection of a 0.6~ml mixture of 0.315 mg/ml fentanyl and 
10 mg/ml fluanisone. After 24 hr, when swelling of the muscle was 
apparent, groups of four rabbits were immobilized, placed prone on 
the gamma camera and injected with either 0.6 ml of 37 MBq 
" mTc-fMLFK-HYNIC or 0.6 ml o f  37 MBq w,nTc-HYNIC- 
MLFOMe in the lateral ear vein.
Images were recorded at 5 min and 1, 4, 8 and 20 hr postinjec­
tion with a single-head gamma camera equipped with a parallel- 
hole low-energy collimator. Images were obtained with a 75% 
symmetrical window over the 140-keV " mTc energy peak. After 
acquisition of 50,000-100,000 counts, the images were digitally 
stored in a 256 X 256 matrix.
The scintigraphic results were analyzed quantitatively by draw­
ing regions of interest over the abscess, the uninfected contralateral 
thigh muscle (background) and the whole body. Abscess-to- 
background ratios and percentage residual activity in the abscess 
(abscess-to-whole body ratio X 100%) were calculated.
After completion of the final images, rabbits were killed with a 
lethal dose of sodium phenobarbital. Samples of blood, infected 
thigh muscle, uninfected contralateral thigh muscle, bone, bone 
marrow, lung, spleen, liver, kidneys and intestines were collected. 
The dissected tissues were weighed and counted in the gamma
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counter. To correct for radioactive decay, injection standards were 
counted simultaneously. The measured activity in samples was 
expressed as %ID/g. Abscess-to-contralateral muscle ratios and 
abscess-to-blood ratios were calculated.
The blood clearance of both labeled peptides was determined in 
groups of three rabbits with intramuscular E. coli infections per 
peptide. Blood samples were collected at 1, 5, 10, 20, 30, 60, 120 
and 240 min after injection of the radiopharmaceuticals. The 
samples were weighed, measured and expressed as %ID/g.
In addition, white blood cell counts were measured in blood 
samples of healthy rabbits after injection of an equal amount of 
" mTc-fMLFK-HYNIC as used in imaging and bio distribution 
studies. Blood samples were obtained at 1, 3, 5, 10, 30 and 60 min
after injection.
Tech fie tin m - 99m -fMLFK-HYNIC in Staphylococcus aureus- and 
Zymosan-Induced Inflammations. S. aureus abscesses were in­
duced in the left thigh muscle of four rabbits as described above, 
with 5 X  108 bacteria in 0.5 ml. Sterile inflammations were 
similarly induced in four rabbits by intramuscular injection o f 1 ml 
of 7.5% zymosan in sterile saline. Twenty-four hours after induc­
tion of the abscesses, rabbits were i,v. injected with 0.6 ml of 37 
MBq " mTc-fMLFK~HYNIC. The gamma camera imaging and 
determination of tissue bio distribution were performed as de­
scribed above.
Statistical Analysis
All values are expressed as mean ±  s.e.m. Statistical analysis 
was performed using a one-way ANOVA.
RESULTS 
Radiolabeling and Characterization of the Technetium- 
99m-Labeled Peptides
Technetium~99m-fMLFK-HYNIC was eluted from the col­
umn in two overlapping peaks at 11-14 min. The control 
peptide, 99mTc-HYNIC-MLFOMe, was eluted from the column 
with a similar pattern at 18-21 min. The elution pattern showed 
a small additional peak at 6 min, presumably representing 
T c0 4~, which was typically less than 10%. Reversed-phase 
chromatography analysis o f  the injected preparations did not 
show degradation. The radiochemical purity o f  both radiophar­
maceuticals was >96% .
The binding o f  [3H]fMLF to receptors on PMNs could be 
completely inhibited by fMLFK-HYNIC. The IC50 value of  
fMLFK-HYNIC was 3 ±  2 nM. Nonspecific binding on 
average was less than 15%. In contrast, HYNIC-MLFOMe did 
not show any inhibition at 100 nM. Furthermore, fMLFK- 
HYNIC was an effective inducer o f  superoxide release of PMN, 
with an EC50 value 0.8 ±  0.4 nM.
Animal Studies
Comparison o f  Tech neti urn - 99m -fMLFK-HYNIC and Tech- 
netium-99m-HYNIC-MLFOMe in E, coli Infections. After in- 
jection o f  " mTc-fMLFK-H YNIC in healthy'rabbits, a minimal 
transient reduction in peripheral leukocyte levels of short 
duration was observed: immediately after injection, the white 
blood cell count decreased to 65% o f  the initial level and 
returned to 90%-95% within 3 min after injection (Fig. 1). The 
same pattern was observed in infected rabbits (data not shown).
Technetium-99m-fMLFK-HYNIC and the control peptide, 
" mTc-HYNIC-MLFOMe, rapidly cleared from the blood in a 
similar fashion (Fig. 2). After a fast initial biodistribution, 
" mTc-fMLFK-HYNIC and " mTc-HYNIC-MLFOMe cleared 
with t l/z values o f  16.4 ±  1.4 min and 13.4 ±  0.5 min, 
respectively, within the first hour and thereafter with t lA values 
of 203.2 ± 2 1 . 3  min and 301.4 ±  24.7 min, respectively.
Time (min)
FIGURE 1. White blood cell counts in blood of healthy rabbits after injection 
of " mTc-fMLFK-HYNIC, expressed as percentage of the preinjection value. 
Error bars, s.e.m.
«
Although " mTc-fMLFK-ITYNIC rapidly cleared from circu­
lation, the images clearly showed rapid accumulation in the 
abscess (Fig. 3). The abscesses could already be visualized at 4 
hr postinjection. With time, increased abscess uptake was 
visible, resulting in clearly delineated abscesses at 20 hr 
postinjection. In contrast, the control peptide 9?lmTc-HYNIC- 
MLFOMe cleared from the abscess during the time course of the 
study. In addition, the images showed high uptake o f  " mTc- 
fMLFK-HYNIC in spleen, liver, kidneys and bladder. Uptake in 
the lungs was high immediately after injection but rapidly de­
creased with time. The control peptide, " mTc-HYNIC-MLFOMe, 
showed marked accumulation in gallbladder and bowel.
The percentage residual activity of 99mTc-fMLFK-HYNIC in 
the abscess, derived from quantitative scintigrapic analysis, 
increased from 1.2% ±  0.1% at 5 min postinjection to 4.3% ±  
0.2% at 20 hr postinjection, whereas the residual activity in the 
abscess of the control peptide " mTc-HYNIC-MLFOMe de­
creased with time: from 2.0% ±  0.1% at 5 min postinjection to 
0.5% ±  0.03%o at 20 hr postinjection (Fig. 4). The abscess 
uptake of " mTc~fMLFK-HYNIC was significantly higher from 
1 hr postinjection onward (p <  0.005).
As a result o f  the increased uptake o f  " mTc-fMLFK-HYNIC 
in the abscess and clearance of the background in the course of 
time, the abscess-to-background ratios continuously increased 
from 1.0 ±  0.04 at 5 min postinjection to 5.8 ±  0.9 at 20 hr 
postinjection (Fig. 5). Unlike the increasing ratios o f  " mTc-
Time (min)
FIGURE 2. Blood clearance of 99mTc-fMLFK-HYNIC and 99mTc-HYN!C- 
MLFOMe determined in rabbits with E. coli infection. Data are expressed as 
percentage of the injected dose. Error bars, s.e.m.
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FIGURE 6. Abscess-to-contralateral muscle ratios (■) and abscess-to-blood 
ratios (52), calculated from rabbits with an £  co//-, S. aureus- or zymosan - 
induced abscess, injected with 99mTc-fMLFK-HYNIG or " mTc-HYNIC-ML~ 
FOMe (£ coli only). Error bars, s.e.m.
DISCUSSION
Our results indicate that accumulation of fMLFK-HYNIC in 
acute infection and sterile inflammation takes place by virtue of 
binding to receptors on locally present PMNs and monocytes. 
The studied chemotactic peptide fMLFK-HYNIC was retained 
in infection, whereas a size-matched control peptide with low 
receptor binding affinity cleared from the infection with time.
To study the hypothesis o f  specific retention of fMLFK- 
HYNIC in infection and inflammation, we searched for a 
control agent with the most favorable characteristics for this 
purpose. HYNIC-MLFOMe met the requirements because it 
was a similar-sized peptide that highly resembled fMLFK- 
HYNIC and had a significantly lower affinity for receptors on 
PMNs and monocytes. Because it was more hydrophobic than 
fMLFK-HYNIC, a different route o f  clearance was observed. 
As shown by the scintigraphic data as well as by tissue 
biodistribution, fMLFK-HYNIC was cleared via both the kid­
neys and liver. Hepatobiliary clearance was the main route of  
clearance o f  HYNIC-MLFOMe. As a result, high activity 
uptake in liver, gallbladder and bowel was visible. Despite 
different routes o f  clearance, blood clearances o f  the two 
peptides was similar. Therefore, localization in infection could 
be compared. The different behavior o f  fMLFK-HYNIC com­
pared to HYNIC-MLFOMe in terms o f  uptake of fMLFK“ 
HYNIC in the abscess and clearance o f  HYNIC-MLFOMe 
from the abscess could be attributed to differences in receptor
binding. The binding of fMLFK-HYNIC to receptors on leu­
kocytes is furthermore reflected in high uptake o f the agent in 
spleen and liver. In addition, the observation that mTc-tricine 
did not accumulatc in infection provided further evidence of 
specific receptor binding of fMLFK-HYNIC in inflammatory 
tissue (data not shown). These data are in line with data reported 
by Babich et al. (12). They found a correlation between the 
infection localization properties o f chemotactic peptides in vivo 
and the fMLF receptor affinity, as determined in vitro. Non­
specific accumulation did not contribute significantly to infec­
tion localization.
Our data demonstrated that fMLFK-HYNIC localizes in both 
infection and sterile inflammation. These findings contradict 
results obtained by Fischman et al. They reported infection 
selective localization of chemotactic peptides, based on the 
observation that low levels of peptide were found in uninfected 
thermally injured tissues in rabbits (13,14) and sterile inflam­
mations induced by intramuscular injection of anesthetic agents 
in nonhuman primates (75). However, assuming that the mech­
anism of localization of chemotactic peptides at sites o f inflam­
mation takes place by virtue of binding to reccptors on PMNs 
and monocytes, it is to be expected that infiltration o f signifi­
cant numbers of these cells in tissue damaged by a sterile agent 
can be visualized with labeled chemotactic peptides. Therefore, 
most likely, accumulation of chemotactic peptide was not found 
in the described sterile lesions used by Fischman et al. because 
of a lack of cellular infiltration. This would be in agreement 
with low accumulation of peptide in turpentine induced inflam­
matory foci (data not shown), which are characterized by 
significant increased vascular permeability but minimal granu­
locyte infiltration (¡6,17). Apparently, increased vascular per­
meability only does not result in localization of the peptide at 
the site of the lesion. Other data support these suggestions: 
chemotactic peptides accumulate in chronic intestinal inflam­
mation in rats and in lungs of rats with infiltration of neutrophils 
as a result of severe trauma (18,19). In accordance with these 
reports, our results demonstrate accumulation of chemotactic 
peptide in zymosan-induced sterile inflammation, an inflamma­
tion characterized by infiltration of PMNs and monocytes 
(20,21).
The slightly lower uptake of fMLFK-HYNIC in the zymo­
san-induced sterile inflammation compared to the uptake in E. 
coli- and S. aureus-induced infections could be explained by 
differences in severity of the inflammation. Injection of E. coli 
and S. aureus induced more severe inflammation than could be 
obtained by injection o f zymosan. In fact, the severity of the 
infection can be increased by injection of more bacteria. Babich
TABLE 1
Biodistribution of Technetium-99m-fMLFK-HYNIC in the E. coli, S. aureus and Zymosan Models and of Technetium-99m-HYNIC
MLFOMe in the £  coli Model at 20 hr Postinjection (%iD/g, Mean Values ± s.e.m.)
Organ
Blood
Abscess
Muscle
Bone
Marrow
Lung
Spleen
Kidney
Liver
Intestine
Feces
HYNIC-MLFOMe
0.005
0.005
0.001
0.002
0.002
0.003
0.003
0.020
0.013
0.073
0.196
± 0.001 
± 0.0003 
± 0.0004 
± 0.001 
± 0.001 
± 0.0003 
± 0.001 
± 0.004 
± 0.005 
0.057 
0.065
£  coli
fMLFK-HYNIC
0.005 ± 
0.049 ± 
0.001 ± 
0.007 ± 
0.036 ± 
0.025 ± 
0.430 ± 
0.145 ± 
0.094 ± 
0.033 
0.028 i
0.0003
0.011
0.0003
0.005
0.013
0.010
0.111
0.014
0.017
0.014
0.011
S. aureus
0.005
0.056
0.001
0.01
0.047
0.048
0.501
0.138
0.114
0.052
0.052
± 0.001 
± 0.012 
± 0.0003 
± 0.002 
± 0.009 
± 0.024 
± 0.231 
± 0.021 
± 0.007 
± 0.041 
± 0.025
Zymosan
0.004
0.035
0.001
0,006
0.050
0.015
0.327
0.163
0.067
0.088
0.016
± 0.001 
± 0.007 
± 0.0002 
± 0,005 
± 0,026 
± 0.004 
± 0.066 
± 0.030 
± 0.011 
± 0.050 
± 0.013
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et al. (2 ) obtained higher uptake values o f  fMLFK-HYNIC in E. 
coli abscesses with 1 X 1011 bacteria than we reported for 
similar abscesses by injection o f 1.5 X 10 10 bacteria. We could 
not inject more E. coli because we used the maximum obtain­
able E. coli. concentration. S. aureus was more pathogenic; less 
bacteria (5 X I08) induced more severe infections compared to
E. coli, resulting in even higher uptake in S. aureus infections. 
Concentrations o f  S. aureus o f 5 X 109 bacteria/ml were lethal. 
For induction o f  the sterile inflammations, we used the maxi­
mum obtainable concentration o f zymosan, which was as high 
as 7.5%.
The specific activity o f  the injected preparation could not be 
determined because the diluted concentrations o f  fMLFK- 
HYNIC used did not have appreciable UV absorbance at 
280 nm. However, in vivo, the induced transient neutropenia 
appeared to be minimal and o f short duration, indicating that 
excess o f  unlabeled fMLFK-HYNIC had been removed by 
reversed-phase chromatography and that minimal amounts o f  
fMLFK-HYNIC were injected in the rabbits, A  study in 
nonhuman primates (22) showed that a similar minimal de­
crease in white blood cell count o f  short duration was observed 
when a dose as low as 10 ng/kg o f chemotactic peptide was 
injected.
It has been shown that the nature o f  the coligand has effects 
on the biodistribution o f  " mTc-labeled HYNIC-derivatized 
chemotactic peptides (23). Most previous studies with these 
peptides have used glucoheptonate as coligand for the radiola­
beling. Nevertheless, tricine was selected for our studies be­
cause, in the same animal model, higher abscess uptake as well 
as higher abscess-to-background ratios were obtained with 
tricine compared to glucoheptonate (data not shown).
CONCLUSION
Both acute infection and sterile inflammation can be specif­
ically targeted with radiolabeled chemotactic peptides, provided 
that these lesions are characterized by sufficient infiltration o f  
PMNs and monocytes. Therefore, in principal, distinction 
between infection and inflammation cannot be made. The 
lesions could be visualized as early as 4 hr after injection. High 
focal uptake was obtained. More studies are required to evaluate 
whether chemotactic peptides are suitable agents for detection 
of chronic inflammatory diseases because most tested models 
thus far concerned acute infection or inflammation,
Several in vivo characteristics o f  chemotactic peptides need 
to be optimized. Detection o f lesions localized in liver, spleen, 
kidneys or even bowels, especially in the case o f less severe 
lesions, will be difficult to detect with chemotactic peptides 
because o f  high physiologic uptake in these organs. Because 
this is a major limitation o f almost every infection detection 
agent, possible ways to modify the peptides to decrease back­
ground activity in the abdomen should be explored. In addition, 
reduction o f  biologic activity o f chemotactic peptides w ill be 
necessaiy to apply chemotactic peptides clinically. The devel­
opment o f  a high specific activity " mTc-labeling has been a 
step in the right direction but does not warrant safe administra­
tion to humans. Therefore, further research in this area should 
focus on the development o f antagonists or biologically less 
active agonists with similar binding characteristics.
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